116 related articles for article (PubMed ID: 31381132)
1. Severe vitamin D deficiency associated with BRAF-mutated melanoma.
Fearfield L; Nobbs J; Petruckevitch A; Harland C
Br J Dermatol; 2019 Dec; 181(6):1343. PubMed ID: 31381132
[No Abstract] [Full Text] [Related]
2. Melanoma with BRAF Mutation in Circulating Cell-free DNA despite no Mutation in the Primary Lesion: A Case Report.
Ashida A; Uhara H; Mikoshiba A; Sakaizawa K; Kumagai N; Koga H; Okuyama R
Acta Derm Venereol; 2016 Jan; 96(1):128-9. PubMed ID: 26123241
[No Abstract] [Full Text] [Related]
3. Clinicopathological features, vitamin D serological levels and prognosis in cutaneous melanoma of shield-sites: an update.
Paolino G; Moliterni E; Didona D; Garelli V; Corsetti P; Lopez T; Richetta AG; Cantisani C; Bottoni U; Calvieri S
Med Oncol; 2015 Jan; 32(1):451. PubMed ID: 25516505
[TBL] [Abstract][Full Text] [Related]
4. Monitoring vitamin D in the patient with melanoma: impact of sun avoidance on vitamin D levels of patients with melanoma at a U.K. tertiary-referral melanoma service.
Lo MCI; Maraka J; Garioch J; John WG; Moncrieff M
Br J Dermatol; 2017 Jul; 177(1):282-283. PubMed ID: 27639181
[No Abstract] [Full Text] [Related]
5. Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients.
Nijenhuis CM; Huitema AD; Blank C; Haanen JB; van Thienen JV; Rosing H; Schellens JH; Beijnen JH
J Clin Pharmacol; 2017 Jan; 57(1):125-128. PubMed ID: 27365214
[No Abstract] [Full Text] [Related]
6. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
[TBL] [Abstract][Full Text] [Related]
7. Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors.
Falanga A; Marchetti M; Massi D; Merelli B; Verzeroli C; Russo L; Rulli E; Tondini C; Legramandi L; Nassini R; Scatena C; De Logu F; Cattaneo L; Mandalà M
J Am Acad Dermatol; 2016 Jun; 74(6):1254-1256.e4. PubMed ID: 27185428
[No Abstract] [Full Text] [Related]
8. Population-based analysis of the prevalence of BRAF mutation in patients diagnosed with cutaneous melanoma and its significance as a prognostic factor.
Rubió-Casadevall J; Carbó-Bagué A; Puigdemont M; Osca-Gelis G; Oliveras G; Vilar-Coromina N; Ferrer-Fabrega B; Urban A; Llobet-Roma M; Martín-Romero F; Perez-Bueno F; Marcos-Gragera R
Eur J Dermatol; 2021 Oct; 31(5):616-622. PubMed ID: 34789445
[TBL] [Abstract][Full Text] [Related]
9. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.
Hugdahl E; Kalvenes MB; Puntervoll HE; Ladstein RG; Akslen LA
Br J Cancer; 2016 Mar; 114(7):801-8. PubMed ID: 26924424
[TBL] [Abstract][Full Text] [Related]
10. Enhanced detection of BRAF-mutants by pre-PCR cleavage of wild-type sequences revealed circulating melanoma cells heterogeneity.
Fusi A; Berdel R; Havemann S; Nonnenmacher A; Keilholz U
Eur J Cancer; 2011 Sep; 47(13):1971-6. PubMed ID: 21570823
[TBL] [Abstract][Full Text] [Related]
11. Distinctive clinical and dermoscopic features of BRAF V600K mutated melanomas.
Ponti G; Manfredini M; Tomasi A; Pellacani G
Br J Dermatol; 2015; 172(5):1438-40. PubMed ID: 25323827
[No Abstract] [Full Text] [Related]
12. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
13. Circulating Tumour DNA Reflects Tumour Burden Independently of Adverse Events Caused by Systemic Therapies for Melanoma.
Ashida A; Sakaizawa K; Mikoshiba A; Kiniwa Y; Okuyama R
Acta Derm Venereol; 2019 Nov; 99(12):1184-1185. PubMed ID: 31396634
[No Abstract] [Full Text] [Related]
14. Allele specific Taqman-based real-time PCR assay to quantify circulating BRAFV600E mutated DNA in plasma of melanoma patients.
Pinzani P; Salvianti F; Cascella R; Massi D; De Giorgi V; Pazzagli M; Orlando C
Clin Chim Acta; 2010 Sep; 411(17-18):1319-24. PubMed ID: 20576522
[TBL] [Abstract][Full Text] [Related]
15. BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha.
Tas F; Erturk K
Cancer Chemother Pharmacol; 2019 Sep; 84(3):521-526. PubMed ID: 30997532
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
17. Quantitative analysis of the BRAF
Ashida A; Sakaizawa K; Mikoshiba A; Uhara H; Okuyama R
Int J Clin Oncol; 2016 Oct; 21(5):981-988. PubMed ID: 27041702
[TBL] [Abstract][Full Text] [Related]
18. Is it good or bad to find a BRAF mutation?
Flaherty KT
J Clin Oncol; 2011 Apr; 29(10):1229-30. PubMed ID: 21343552
[No Abstract] [Full Text] [Related]
19. Usefulness of immunocytochemistry for the detection of the BRAF(V600E) mutation in circulating tumor cells from metastatic melanoma patients.
Hofman V; Ilie M; Long-Mira E; Giacchero D; Butori C; Dadone B; Selva E; Tanga V; Passeron T; Poissonnet G; Emile JF; Lacour JP; Bahadoran P; Hofman P
J Invest Dermatol; 2013 May; 133(5):1378-81. PubMed ID: 23303445
[No Abstract] [Full Text] [Related]
20. Clinicopathological features and clinical outcomes associated with TP53 and BRAF
Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA
Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
